Semax - Neuroprotective Peptide for Cognitive Research

By Medical Team of Generic Peptides

In the 1950s, endocrinologists studying adrenocorticotropic hormone (ACTH) — the pituitary hormone that tells your adrenal glands to make cortisol — noticed something strange. Patients receiving ACTH for medical conditions often reported improved cognitive function: sharper memory, better attention, clearer thinking. This wasn't explained by cortisol effects. ACTH seemed to be doing something directly to the brain, independent of its hormonal role.

Over the next three decades, researchers systematically broke ACTH down into fragments, looking for the piece responsible for the cognitive effects. They narrowed it to amino acids 4-10, a seven-amino-acid segment that retained the nootropic properties without stimulating the adrenals. But this fragment had the same problem as most peptides: degraded in minutes by peptidases. Useless as a drug.

In the 1980s, the Institute of Molecular Genetics of the Russian Academy of Sciences, led by Nikolai Myasoedov, applied the same engineering approach they'd use years later for Selank. They truncated ACTH(4-10) slightly and added a Pro-Gly-Pro (PGP) tail to the C-terminus — a proline-rich structure that resists enzymatic breakdown. The resulting heptapeptide became Semax — from Russian "семь аминокислот" meaning "seven amino acids." [1]

Today, Semax is on Russia's List of Vital and Essential Drugs. It's prescribed in Russia and Ukraine for stroke recovery, cognitive disorders, and ischemic brain injury. Outside those countries, it exists in a peculiar gray zone — a real pharmaceutical with decades of clinical use in one hemisphere, and an unknown research compound everywhere else.

Semax: what it is and how it works in a nutshell

Semax is a synthetic heptapeptide (sequence: Met-Glu-His-Phe-Pro-Gly-Pro) — the ACTH(4-7) fragment extended with a Pro-Gly-Pro tail for stability. It's the sister compound to Selank — developed by the same research institute using the same PGP-stabilization strategy, but from a different parent peptide.

Crucial distinction: despite being derived from ACTH, Semax does NOT stimulate cortisol production or affect the adrenal axis. The amino acids that activate the MC2R receptor (the adrenal ACTH receptor) are in the N-terminal portion of ACTH, which Semax lacks. This dissociation was a deliberate design goal — keep the nootropic effects, remove the hormonal effects [2].

Regulatory status:

• Approved in Russia and Ukraine for ischemic stroke, transient ischemic attack, dyscirculatory encephalopathy, cognitive disorders, optic nerve atrophy, and cognitive rehabilitation
• Listed on Russia's List of Vital and Essential Drugs (approved December 2011)
• Not FDA-approved in the US, not EMA-approved in Europe
• Available as a 0.1% nasal drop solution (general use) and 1% solution (intensive clinical applications)

Like Selank, this is one of the few peptides covered on this blog with real regulatory approval somewhere in the world — just not where most readers live.

Semax mechanism of action: what it actually does in the body

Semax works through multiple mechanisms that reinforce each other. No single clean receptor story — instead, a coordinated effect on neurotrophic factors, neurotransmitter systems, and gene expression.

1. BDNF upregulation (the main story)

The most replicated finding in Semax research is its effect on brain-derived neurotrophic factor (BDNF) — the single most important neurotrophin for adult brain plasticity, synaptic growth, and learning.

The foundational Dolotov et al. (2006) study showed that a single intranasal dose of Semax (50 mcg/kg) in rats produced [3]:

• 1.4-fold increase in BDNF protein levels in the hippocampus
• 3-fold increase in BDNF mRNA (exon III)
• 1.6-fold increase in TrkB receptor phosphorylation (TrkB is the receptor BDNF binds)
• 2-fold increase in TrkB mRNA

This is a major pharmacological finding. Most Western nootropics produce subtle neurochemical changes — Semax rapidly and reliably triples BDNF transcription after a single dose. Increasing BDNF alongside its receptor is even more significant than either alone, because BDNF without adequate TrkB has limited functional impact.

Why BDNF matters: it's the primary driver of long-term potentiation — the cellular mechanism underlying memory formation. Low BDNF is associated with depression, cognitive decline, Alzheimer's disease, and reduced neuroplasticity. Compounds that reliably raise BDNF are rare and pharmacologically valuable.

2. Melanocortin receptor activity

Semax acts as a partial agonist at melanocortin-4 receptors (MC4R) in the brain [4]. MC4R activation triggers cAMP/PKA and MAPK/ERK signaling cascades that promote neuronal plasticity and survival. This mechanism is particularly relevant to learning, memory, inflammation modulation, and neuroprotection.

As mentioned above, Semax does NOT activate MC2R (the adrenal receptor) or MC1R (skin pigmentation) significantly. This receptor selectivity is pharmacologically important.

3. Serotonergic and dopaminergic modulation

Intranasal Semax increases serotonin levels in the hippocampus and several cortical regions. Dopamine effects are more modest but positive in attention-relevant circuits. It also potentiates the stimulatory effects of d-amphetamine — a mechanistic finding, not a combination recommendation [5].

4. NGF and VEGF enhancement

Beyond BDNF, Semax increases expression of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF). NGF supports cholinergic neurons critical for attention and memory. VEGF supports brain microvascular health, which is particularly relevant to stroke recovery applications.

5. Transcriptomic effects

Modern research using microarrays has shown Semax modulates expression of hundreds of genes involved in neuronal survival, synaptic plasticity, and neurotransmitter metabolism — suggesting its effects go well beyond single-pathway pharmacology [6].

Pharmacokinetics. Short plasma half-life (roughly 30 minutes), but clinical effects persist 8-24 hours because the peptide triggers downstream gene expression changes that outlast the molecule itself. This is why Semax doesn't require sustained blood levels to work — it kicks off processes that continue after the peptide is gone.

Who uses Semax and what for

• Post-stroke patients in Russia and Ukraine — the Russian-approved indication. Gusev et al. (1997) and subsequent trials established efficacy in acute ischemic stroke recovery, with improvements in neurological outcomes and infarct volume reduction [7].
• People with cognitive decline or age-related memory issues — used clinically for mild cognitive impairment and early dementia in Russian practice.
• Students, professionals, and cognitive performance seekers — the largest off-label user group worldwide. Used for improved learning, focus, and memory during demanding cognitive work.
• People with ADHD-like attention issues — off-label use. The dopaminergic and neurotrophic effects provide a different approach than classical stimulants.
• People with mild depression or anxiety with cognitive features — BDNF upregulation overlaps with antidepressant mechanisms. Some use Semax adjunctively.
• Patients recovering from traumatic brain injury or concussion — based on the neuroprotective mechanism.
• People with optic nerve conditions — the Russian approval specifically includes optic nerve atrophy, reflecting research on neurotrophic support for retinal ganglion cells.

Realistic expectations during a 10-14 day course at standard doses: improved mental clarity, better memory recall, enhanced focus on demanding tasks, mild mood elevation, subjective sense of cognitive "smoothness." Effects typically build over days — don't expect dramatic Day 1 changes.

What WON'T happen: stimulant-like immediate wakefulness (it's neurotrophic, not pharmacological stimulation), dramatic IQ increases (it enhances baseline function, doesn't elevate intelligence beyond your natural range), cure for serious psychiatric conditions (it's an adjunct, not primary psychiatric medication), instant effect (Day 1-3 people often feel subtle changes, the full effect develops over a course).

What Semax stacks with: popular combinations

• Semax + Selank — the classic Russian neuropeptide stack. Semax for cognitive enhancement, Selank for anxiolysis. Focus + calm in complementary mechanisms.
• Semax + B vitamins (especially methylcobalamin, P-5-P, methylfolate) — supports the methylation and neurotransmitter synthesis pathways that BDNF signaling feeds into.
• Semax + Omega-3 fatty acids (especially DHA) — DHA supports BDNF signaling and synaptic membrane function. Synergistic with Semax's neurotrophic effects.
• Semax + Lion's Mane mushroom — both upregulate NGF through different mechanisms. Common combination in nootropic stacks.
• Semax + Cerebrolysin — another Eastern European neuropeptide product used for cognitive and stroke recovery. Occasionally combined in clinical protocols.

Generally not combined with: other melanocortin-active compounds (Melanotan II), high-dose stimulants (unpredictable amplification).

Semax side effects and risks

One of the cleanest side effect profiles of any peptide covered on this blog. Decades of clinical use in Russia and Ukraine with no major safety issues identified.

Reported in clinical use (typically mild):

• Mild nasal irritation (intranasal formulation) — transient
• Slight euphoria or stimulant-like feeling — some users, uncommonly
• Mild sleep disturbance if taken too late in the day — reversible by timing
• Headache — uncommon, mild when it occurs
• Mild increase in blood glucose in diabetics (~7.4% of patients in clinical data) [8]
• Injection site reactions — with subcutaneous use, minor

Notably NOT reported:

• No cortisol elevation — confirmed in clinical studies
• No adrenal stimulation — mechanism specifically excludes MC2R
• No tolerance or dependence — Semax works through gene expression changes, not receptor occupancy
• No withdrawal syndrome — consistent with the mechanism
• No evidence of neurotoxicity — in contrast to some stimulant nootropics

Who should be cautious or avoid:

• Pregnant or breastfeeding women (no safety data)
• People with severe psychiatric conditions (schizophrenia, bipolar disorder) — poorly studied
• Anyone with significant thyroid disorders (minor interaction concerns)
• People with severe cardiovascular disease (the mild stimulating effect warrants caution)
• Children under medical supervision only (Russia does use it in pediatric neurological contexts under physician oversight)

The honest regulatory framing: like Selank, Semax is approved in Russia and Ukraine but not Western regulatory systems. The safety record in Russian clinical use is reassuring but not a substitute for full FDA/EMA validation. Most Russian trials are smaller, Russian-language, and not independently replicated in large Western studies.

How to use and store Semax

Russian approved formulation: 0.1% intranasal drops (1 mg/mL). The 1% formulation (10 mg/mL) is used for acute clinical applications like stroke recovery under medical supervision.

Typical protocols:

• Standard nootropic dose: 600-1200 mcg per day, typically split as 300 mcg intranasally 2-4 times daily
• Cognitive enhancement / study protocols: 600-900 mcg/day
• Stroke rehabilitation (Russian clinical): 6000-9000 mcg/day (much higher dose, under medical supervision)
• Cycle: 10-14 days on, 2-4 weeks off is common. Continuous use is also used in Russian practice without reported tolerance.
• Timing: morning and early afternoon doses preferred. Avoid evening doses to prevent sleep disruption.
• Route: intranasal is strongly preferred. The peptide crosses the cribriform plate into the brain, bypassing the blood-brain barrier partially. Subcutaneous works but is less efficient for CNS effects.

Storage: lyophilized form in freezer at -20°C. Reconstituted nasal spray refrigerated at 2-8°C, used within 21-30 days. Russian pharmaceutical formulations have specific commercial storage requirements per manufacturer labeling.

Semax vs alternatives: what's different

• Selank — sister peptide, same research institute, GABAergic/anxiolytic focus rather than BDNF/neurotrophic. Often stacked with Semax.
• Cerebrolysin — Austrian neuropeptide preparation (mixture of multiple peptides from pig brain) used clinically for cognitive disorders. Different composition, similar clinical indications, longer history but less characterized mechanism.
• Noopept — synthetic nootropic from the same research tradition. Oral, cheap, different mechanism (prolyl endopeptidase modulation, cycloprolylglycine metabolite).
• Modafinil / armodafinil — Western wakefulness-promoting agents. Strong acute effect, pharmacological stimulation, different mechanism entirely. Better for acute wakefulness, less for long-term cognitive resilience.
• Racetams (piracetam, aniracetam) — older nootropics, cheap, milder effects, different cholinergic mechanisms.

Semax's distinguishing feature: the strongest validated BDNF-upregulating peptide with decades of clinical use, combining neurotrophic, neurotransmitter, and gene expression effects without stimulating the adrenals or causing tolerance. For sustained cognitive resilience and neuroprotection (rather than acute stimulation), it occupies a rare niche.

Myths about Semax

• "Semax gives you a drug-like high or limitless-style cognitive boost." Semax's effects are subtle and cumulative. Most users describe "clearer thinking" or "easier focus" rather than anything dramatic. Anyone expecting amphetamine-like effects is misunderstanding the mechanism. It's a neurotrophic compound, not a stimulant.
• "Because it comes from ACTH, Semax must raise cortisol." This is the most common misconception and it's wrong. The cortisol-stimulating portion of ACTH is in amino acids 1-24. Semax is derived from the 4-7 fragment, which has the cognitive effects without hormonal activity. Dedicated clinical studies confirm no cortisol elevation.

Sources

1. Ashmarin, I. P., Nezavibatko, V. N., Myasoedov, N. F., Kamensky, A. A., Grivennikov, I. A., Ponomareva-Stepnaya, M. A., Andreeva, L. A., Kaplan, A. Y., Koshelev, V. B., & Ryasina, T. V. (1997). A nootropic adrenocorticotropin analog 4-10-Semax (15 years experience in its design and study). Zhurnal Vysshei Nervnoi Deyatel'nosti Imeni I P Pavlova, 47(2), 420-430. — foundational paper by the lead developers describing Semax design and early clinical experience.
2. Ashmarin, I. P., Lelekova, T. V., & Sanzhieva, L. Ts. (2005). [The role of regulatory peptides in the integrative functions of the organism]. Bulletin of Experimental Biology and Medicine, 139, 453-458. — context on regulatory peptides including Semax and its dissociation from ACTH hormonal effects.
3. Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Y., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54-60. https://pubmed.ncbi.nlm.nih.gov/16996037/ — the landmark study documenting BDNF/TrkB upregulation.
4. Kolomin, T., Shadrina, M., Slominsky, P., Limborska, S., & Myasoedov, N. (2013). A new generation of drugs: synthetic peptides based on natural regulatory peptides. Neuroscience and Medicine, 4(4), 223-252. — review covering Semax's melanocortin receptor activity and dissociation from adrenal effects.
5. Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493-1500. — documents monoaminergic effects of Semax.
6. Filippenkov, I. B., Stavchansky, V. V., Glazova, N. Y., Sebentsova, E. A., Remizova, Yu. A., Valieva, L. V., Levitskaya, N. G., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Effects of Semax on the transcriptome of the rat brain during ischemia. Doklady Biochemistry and Biophysics, 491(1), 90-93. — modern transcriptomic data on Semax's broad gene expression effects.
7. Gusev, E. I., Skvortsova, V. I., Miasoedov, N. F., Nezavibat'ko, V. N., Zhuravleva, E. Yu., & Vanichkin, A. V. (1997). [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova, 97(6), 26-34. — foundational clinical trial establishing efficacy in acute stroke.
8. Kolomin, T., Shadrina, M., Agapova, T., Slominsky, P., Shram, S., Limborska, S., & Myasoedov, N. (2013). Mechanisms of action of the peptide drugs Semax and Selank, based on gene expression changes in the brain. Journal of Alzheimer's Disease & Parkinsonism, 3(2), 114. — comprehensive review of clinical safety data across Russian applications.

Semax Dosage Guide

Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia as a stable analog of the ACTH(4–10) fragment, with a Pro-Gly-Pro C-terminal extension that dramatically extends half-life. Unlike full-length ACTH, it retains neurotrophic activity without stimulating cortisol release. It rapidly upregulates BDNF and its TrkB receptor in the hippocampus, modulates dopaminergic and serotonergic signaling, and inhibits enkephalinase — producing cognitive enhancement, neuroprotection, and mood support. This guide is aimed at users seeking a nootropic with genuine clinical pedigree (approved in Russia for ischemic stroke recovery and cognitive impairment), those studying neuroprotection protocols, and nootropic stackers pairing it with Selank. Dosing below combines the Russian 0.1% and 1% intranasal prescribing protocols, the Gusev ischemic stroke trials (6,000–18,000 mcg/day), and the nootropic community cycling frameworks.

Real-World Dosage Protocols by Experience Level

Doses also shift depending on the specific goal. The same peptide used for everyday focus versus acute neurological recovery follows dramatically different concentration protocols.

Dosage by Goal

Dose in the morning and early afternoon — Semax has stimulating and mildly dopaminergic properties, so evening dosing commonly causes insomnia and vivid dreams. The plasma half-life is only 2–5 minutes, but downstream BDNF upregulation peaks at 3–8 hours and persists 24+ hours, which is why dosing frequency is set by this neurotrophic window rather than by plasma kinetics. Cycle rather than running continuously — Russian clinical protocols and community practice both favor 5–14 day courses followed by equal or longer breaks, both to match the evidence base and to prevent any theoretical receptor adaptation. Use caution combining with SSRIs, MAOIs, or other serotonergic compounds given Semax's monoaminergic activity, and avoid in anyone with a seizure disorder, as theoretical pro-convulsant effects have been noted at very high doses.

Semax Storage Guide: How to Keep Your Research Peptide Stable and Effective

Semax ships as a white lyophilized powder in a sealed glass vial, freeze-dried to preserve its heptapeptide structure and extend its shelf life. With a few simple habits — cold, dark, dry — the sealed vial stays in perfect condition for its full shelf life. Here's exactly how to store it.

Lyophilized Powder (Unreconstituted)

Shipping & Product Authenticity

Every order is processed quickly and shipped with full tracking. All products come directly from the official Generic Peptides supply chain — in original manufacturer packaging, carefully handled from warehouse to your door.

Shipping Times

Direct Supply & Secure Delivery

This product is supplied through the official Generic Peptides distribution chain and shipped in original manufacturer packaging. Orders are packed securely to protect the contents during transit and to respect customer privacy as a standard practice.

Outer packaging is neutral and does not display product details on the exterior — a common approach to protect shipments from damage, tampering, and unnecessary exposure during delivery.

What to Expect

• Orders are processed after payment confirmation
• USA domestic shipping is typically faster when local stock is selected
• International orders include tracking, though update frequency may vary by destination
• Multiple warehouses may result in separate shipments when applicable

Authenticity & Verified Supply

Every order includes full authenticity assurance: official Generic Peptides presentation, batch-linked lab documentation, and sealed original packaging — giving customers confidence in every purchase.

Shipping & Returns